A Ari, GB Moody. How to deliver aerosolized medications through high flow nasal cannula safely and effectively in the era of COVID-19 and beyond: A narrative review. Can J Respir Ther 2021;57:22–25. doi: 10.29390/cjrt-2020-041.

**Background:** The treatments of COVID-19 involve some degree of uncertainty. Current evidence also shows mixed findings with regards to bioaerosol dispersion and airborne transmission of COVID-19 during high flow nasal cannula (HFNC) therapy. While coping with this global pandemic created hot debates on the use of HFNC, it is important to bring detached opinions and current evidence to the attention of health care professionals (HCPs) who may need to use HFNC in patients with COVID-19.

**Aim:** The purpose of this paper is to provide a framework on the selection, placement, and use of nebulizers as well as HFNC prongs, gas flow, and delivery technique via HFNC to help clinicians deliver aerosolized medications through HFNC safely and effectively in the era of COVID-19 and beyond.

**Methods:** We searched PubMed, Medline, CINAHL, and Science Direct to identify studies on aerosol drug delivery through HFNC using the following keywords: (“aerosols,” OR “nebulizers”) AND (“high flow nasal cannula” OR “high flow oxygen therapy” OR “HFNC”) AND (“COVID-19,” OR “SARS-CoV2”). Twenty-eight articles including in vitro studies, randomized clinical trials, scintigraphy studies, review articles, prospective and retrospective research were included in this review.

**Discussion and results:** It is not clear if the findings of the previous studies on bacterial contamination could be applied to viral transmission because they do not provide data that could be extrapolated to the risk of SARS-CoV2 transmission. In the face of the unknown risk with the transmission of COVID-19 during HFNC therapy, the benefits of HFNC must be weighed against the risk of infection to HCPs and other patients. Due to the limited number of ventilators available in hospitals and the confirmed effectiveness of HFNC in treating hypoxemic respiratory failure, HFNC may prevent early intubation, and prolonged intensive care unit stays in patients with COVID-19.

**Conclusion:** Clinicians should review the magnitude of this risk based on current evidence and use the suggested strategies of this paper for safe and effective delivery of aerosolized medications through HFNC in the era of COVID-19 and beyond.

**Key Words:** high flow nasal cannula; aerosols; nebulizers; drug delivery; COVID-19; infection control

---

**INTRODUCTION**

As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an ever-greater risk to individual and community health worldwide, the number of critically ill patients with COVID-19 who require intensive care increased significantly. Given the rapid spread of SARS-CoV-2 and the limited number of ventilators available in the intensive care units (ICUs), using high flow nasal cannula (HFNC) in patients with hypoxemic respiratory failure has become an integral component of the global response to this pandemic as it may reduce the need for ventilatory support compared with conventional oxygen therapy [1, 2]. However, there are detached opinions on the use of HFNC in this patient population.

Some clinicians do not want to use HFNC for aerosol delivery to patients with COVID-19, because they think that the dispersion of bioaerosol to the environment is high and increased bioaerosol dispersion may lead to a viral transmission. Others believe that the HFNC should be used for the delivery of aerosolized medication in the era of COVID-19 due to its effectiveness in the treatment of hypoxemic respiratory failure. Also, early intubation is considered a high-risk procedure for COVID-19, and prolonged ICU stay is an issue due to the limited number of ventilators available. Therefore, the purpose of this paper is to review detached opinions and provide strategies for the safe and effective delivery of aerosolized medications through HFNC in the era of COVID-19 and beyond.

**METHODS**

We searched PubMed, CINAHL, and Science Direct from June 1, 2005 to December 25, 2020, to identify studies on aerosol drug delivery through HFNC. The following keywords were used in the search of relevant publications: (“aerosols,” OR “nebulizers”) AND (“high flow nasal cannula” OR “high flow oxygen therapy” OR “HFNC”) AND (“COVID-19,” OR “SARS-CoV-2”). Although a total of 77 articles were identified; abstracts, letters to the editor, and studies published in a language other than English were excluded. Twenty-eight articles that are in vitro studies, randomized clinical trials, scintigraphy studies, review articles, prospective and retrospective research were included in this review (Figure 1). Two reviewers independently assessed the eligibility of each paper based on the evidence of exhaled air dispersion and viral transmission with HFNC as well as the presence of recommendations on aerosol drug delivery through HFNC in patients with COVID-19.


DISCUSSION

Since one of the main mechanisms of action of HFNC is the washing out of the patient’s pharyngeal deadspace, concerns have been raised that the high flows used to flush expired gas from the upper airway of infected patients may increase bioaerosol dispersion into the environment. Additionally, in some patients, concurrent therapy with inhaled medications may be necessary [3–5], and clinicians are concerned about administering medications through HFNC that might exacerbate the aerosolization and spread of infectious particles to health care professionals (HCPs) or other patients.

Using a direct visualization of exhaled smoke dispersion and similar breathing parameters, Hui et al. [6] and Ip et al. [7] measured the maximum dispersion distance of exhaled smoke particles with the HFNC and oxygen mask, respectively. The dispersion distance of particles via HFNC at 60 L/min shows a similar risk to a simple oxygen mask at 15 L/min [7]. Furthermore, exhaled dispersion distance with the Venturi and nonrebreathing masks was much greater than HFNC [7]. In a clinical study on 19 patients with bacterial pneumonia, Leung et al. [8] compared HFNC at 60 L/min with an oxygen mask at 8.6 L/min on environmental contamination and bacterial growth measured through patient’s room air and settling plates placed at 0.4 m and 1.6 m from patients. They reported no significant difference in bacterial growth in the air sample and settling plates between HFNC and oxygen mask at 1, 2, and 5 days of incubation [8]. A recent in-vitro study also did not show an increase in the potential risk of droplet and contact infection with HFNC [9]. However, SARS-CoV-2 has been shown to survive aerosolization [10], and it is not clear if the findings of these studies on bacterial contamination could be applied to viral transmission, because they do not provide data that could be extrapolated to the risk of SARS-CoV-2 transmission. In the face of the unknown risk with the transmission of COVID-19 during HFNC therapy, the benefits of HFNC must be weighed against the risk of infection to HCPs and other patients.

Currently, there is a limited number of ventilators available in ICUs and early intubation poses a high risk for COVID-19. Due to the confirmed effectiveness, comfort, and convenience of HFNC in the treatment of hypoxic respiratory failure, HFNC may prevent early intubation and prolonged ICU stay in patients with COVID-19. Therefore, reviewing the magnitude of this risk based on current evidence and developing strategies for safe and effective delivery of aerosolized medications through HFNC is essential on a wide scale within and across health care institutions.

Table 1 lists suggestions on how to deliver aerosolized medications through HFNC safely and effectively to patients with COVID-19 [3, 11].

Caregivers were estimated to be exposed to 8.5% and 3.2% of the nebulized loading dose during HFNC therapy at 0.8 m and 2.2 m from the patient, respectively [12]. Placing a surgical mask on the patient’s face [13, 14] and using tightly fitting prongs [6] reduce exhaled air dispersion during HFNC. Also, clinicians should avoid placing an aerosol mask on top of HFNC to deliver aerosols with pressurized metered dose inhalers (pMDIs) or nebulizers because it decreases aerosol drug delivery via HFNC [15] due to physical obstruction/barrier created by the cannula. While some clinicians remove HFNC to use a facemask or mouthpiece for conventional aerosol therapy, the interruption of the HFNC therapy may have some clinical consequences such as the derecruitment of the lungs, the interruption of high flow inspired oxygen therapy and increased work of breathing in patients with COVID-19. To optimize aerosol delivery through HFNC, nebulizers should be placed before the humidifier [11, 16–18]. Thus, the rainout of larger particles will be drained in the humidifier that will lead
TABLE 1
Suggestions for the delivery of aerosolized medications through HFNC safely and effectively in the era of COVID-19 and beyond.

| Suggestions for effective aerosol delivery via HFNC | Suggestions for safe aerosol delivery via HFNC |
|-----------------------------------------------------|------------------------------------------------|
| **Nebulizer selection** | Use an aseptic technique to prevent the contamination of the nebulizer during device preparation. |
| Prefer mesh nebulizers over jet nebulizers due to their greater efficiency during HFNC therapy. | Close the reservoir cap after use. |
| Place the mesh nebulizer at the inlet of the humidifier to improve aerosol delivery through HFNC. | Clean the nebulizer based on the manufacturer’s guidelines. |
| Use larger HFNC cannulas but do not block more than 50% of the cross-sectional area of each nostril. | Make sure HFNC prongs are well fitted and not loose to reduce the dispersion of bioaerosol during therapy. |
| Decrease flow rates during aerosol therapy, if it is tolerated by the patient because aerosol drug delivery is inversely related to gas flow. | Monitor patient to ensure that low flow rate is tolerated by the patient. |
| Return the HFNC flow rate to the initial setting at the end of the nebulization. | Titrate gas flow based on patient’s response to determine optimum flow rate, if possible. |
| **Delivery technique** | Use an aseptic technique to maintain SpO₂ when using low flow rates for aerosol therapy. |
| Do not discontinue HFNC therapy for conventional aerosol therapy. | Place a surgical mask on the face of the patient using HFNC to minimize exhaled air dispersion and viral transmission. |
| Do not place an aerosol mask on top of HFNC to deliver aerosols with pMDIs or nebulizers as it will decrease medication delivery to the patient. | Using an aerosol mask with a nebulizer on top of HFNC will increase bioaerosol dispersion carrying pathogens. |
| Preference of unit dose vs. continuous aerosol nebulization with an infusion pump | Place a surgical mask on the face of the patient using HFNC to minimize exhaled air dispersion and viral transmission. |
| Prefer unit dose to deliver aerosols. | Monitor patient to ensure that low flow rate is tolerated by the patient. |
| Reduce gas flow during nebulization and return the flow rate to initial settings after therapy. | Titrate gas flow based on patient’s response to determine optimum flow rate, if possible. |
| Titrate FiO₂ to maintain SpO₂ when using an infusion pump with HFNC. | Titrate FiO₂ to maintain SpO₂ when using low flow rates for aerosol therapy. |
| Use a higher nominal dose with a low flow rate if continuous nebulization with an infusion pump has to be used for aerosol drug delivery. | |

Note: HFNC, high flow nasal cannula; pMDI, pressurized metered-dose inhaler.

Future research
Although there are many in vitro studies on HFNC, the findings of previous in vitro studies need to be validated through future clinical studies. Studying the impact of aerosol delivery through HFNC on patient safety is warranted. Also, many factors such as the size and air exchange frequency of the room, the type of aerosol device used during therapy, and the movement of people in the room impact aerosol transmission. While previous in vitro studies evaluated some of these factors, more clinical research is needed to determine the impact of these factors on the transmission of bioaerosols in the era of COVID-19 and beyond.

CONCLUSION
The treatments of COVID-19 involve some degree of uncertainty. Current evidence shows mixed findings with regards to bioaerosol dispersion and airborne transmission of COVID-19 during HFNC therapy. While coping with this global pandemic created hot debates on the use of HFNC, it is important to bring detached opinions and current evidence to the attention of HCPs who may need to use HFNC in patients...
How to deliver aerosolized medications

Ari and Moody

with COVID-19. This paper provides a framework on the selection, placement, and use of nebulizers as well as HFNC prongs, gas flow, and delivery technique via HFNC. When initiating HFNC therapy, clinicians should implement suggested strategies for safe and effective delivery of aerosolized medications through HFNC not only in the era of COVID-19 but also in the future.

DISCLOSURES

Competing interest
Dr. Ari discloses relationships with Aerogen Ltd and Philips Healthcare.
Mr. Moody received unrestricted research grants from Aerogen Ltd.

Funding
No funding was obtained in the preparation of this editorial.

Authors’ contributions
Dr. Ari conceived of the idea. Dr. Ari and Mr. Moody performed the literature search and drafted the editorial. All authors reviewed, revised, and approved the paper before submission.

Ethics approval
Not applicable.

REFERENCES

1. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth 2020;67:1217–49. doi: 10.1007/s12630-020-01740-2.

2. Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv 2020;17:133–44. doi: 10.1080/17425247.2020.1712356.

3. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med 2020;167:105987. doi: 10.1016/j.rmed.2020.105987.

4. Ari A. Use of aerosolised medications at home for COVID-19. Lancet Respir Med 2020;8:754–6. doi: 10.1016/S2213-2600(20)30270-8.

5. Ari A. Promoting safe and effective use of aerosol devices in COVID-19: risks and suggestions for viral transmission. Expert Opin Drug Deliv 2020;17:1509–13. doi: 10.1080/17425247.2020.1811225.

6. Hui D, Chow B, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019;53:1802339. doi: 10.1183/13993003.02339-2018.

7. Ip M, Tang JW, Hui DS, et al. Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control 2007;35:684–9. doi: 10.1016/j.ajic.2007.05.007.

8. Leung C, Joynt G, Gomersall C, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect 2019;101:84–7. doi: 10.1016/j.jhin.2018.10.007.

9. Kotoda M, Hishiyama S, Mitsui K, et al. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. J Hosp Infect 2020;104:534–7. doi: 10.1016/j.jhin.2019.11.010.

10. van Doremalen N, Bushmaker T, Morris D, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New Engl J Med 2020;NEJM.2020.03.09.20233217.

11. Ari A. Aerosol drug delivery through high flow nasal cannula. Curr Pharm Biotechnol 2017;18:877–82. doi: 10.2174/1389201019666171219104217.

12. McGrath J, O’Toole C, Bennett G, Joyce M, Byrne M, MacLoughlin R. Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019;11:254. doi: 10.3390/pharmaceutics11060254.

13. Leonard S, Atwood CW Jr., Walsh BK, et al. Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: implications for the high-flow nasal cannula. Chest 2020;158:1046–9. doi: 10.1016/j.chest.2020.03.043.

14. Li J, Fink J, Elshafei A, et al. Placing a mask on COVID-19 patients during high flow nasal cannula therapy reduces aerosol particle dispersion. ERJ Open Res 2021;7(1):359–2020. doi: 10.1188/23120541.00519-2020.

15. Alalwan MA, Fink JB, Ari A. In vitro evaluation of aerosol drug delivery with and without high flow nasal cannula in children. Pediatr Pulmonol 2019;54:1968–73. doi: 10.1002/ppul.24501.

16. Sunbul FS, Fink JB, Harwood R, Sheard MM, Zimmerman RD, Ari A. Comparison of HFNC, bubble CPAP and BiPAP on aerosol delivery in neonates: an in vitro study. Pediatr Pulmonol 2015;50:1099–106. doi: 10.1002/ppul.23113.

17. Li J, Gong L, Ari A, Fink JB. Decrease the flow setting to improve trans-nasal pulmonary aerosol delivery via “high-flow nasal cannula” to infants and toddlers. Pediatr Pulmonol 2019;54:914–21. doi: 10.1002/ppul.24274.

18. Réminiac F, Vécello L, Heute-Younch N, Petticollin A, Respaul R, Cabrera M. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv 2016;29:134–41. doi: 10.1089/jamp.2015.1219.

19. Ari A, Harwood R, Sheard M, Dailey P, Fink JB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol 2011;46:793–801. doi: 10.1002/ppul.21421.

20. Dailey PA, Harwood R, Walsh K, et al. Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care 2017;62:1186–92. doi: 10.4187/respcare.05127.

21. Ari A. Effect of nebulizer type, delivery interface, and flow rate on aerosol drug delivery to spontaneously breathing pediatric and infant lung models. Pediatr Pulmonol 2019;54:1735–41. doi: 10.1002/ppul.24449.

22. Réminiac F, Vécello L, Loughlin RM, et al. Nasal high flow nebulization in infants and toddlers: an in vitro and in vivo scintigraphic study. Pediatr Pulmonol 2017;52:337–44. doi: 10.1002/ppul.23509.

23. Corcoran TE, Saville A, Adams PS, et al. Deposition studies of aerosol delivery by nasal cannula to infants. Pediatr Pulmonol 2019;54:1319–25. doi: 10.1002/ppul.24326.

24. Alcoforado L, Ari A, Barcelar JM, Brandão SCS, Fink JB, de Andrade AD. Impact of gas flow and humidity on trans-nasal aerosol deposition via nasal cannula: a randomized cross-over study. Pharmaceutics 2019;11(7):320. doi: 10.3390/pharmaceutics11070320.

25. Li J, Wei W, Fink JB. In vitro comparison of unit dose vs infusion pump administration of albuterol via high-flow nasal cannula in toddlers. Pediatr Pulmonol 2020;55:322–9. doi: 10.1002/ppul.24589.

26. Li J, Gong L, Fink JB. The ratio of nasal cannula gas flow to patient inspiratory flow on trans-nasal pulmonary aerosol delivery for adults: an in vitro study. Pharmaceutics 2019;11(9):225. doi: 10.3390/pharmaceutics11050225.

27. Dugernier J, Hesse M, Jumetz T, et al. Aerosol delivery with two nebulizers through high-flow nasal cannula: a randomized cross-over single-photon emission computed tomography-computed tomography study. J Aerosol Med Pulm Drug Deliv 2017;30:340–9. doi: 10.1089/jamp.2017.1366.

28. Fink J, Ehrmann S, Li J, et al. Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in medicine. J Aerosol Med Pulm Drug Deliv 2020;33(6):300–4. doi: 10.1089/jamp.2020.1615.